Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMHNYWP)

Drug Name
ISIS-GCGR Drug Info
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Phase 2 [1]
Type-2 diabetes 5A11 Preclinical [2]
Cross-matching ID
TTD Drug ID
DMHNYWP

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon receptor messenger RNA (GCGR mRNA) TTLMJSC GLR_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Glucagon receptor messenger RNA (GCGR mRNA) DTT GCGR 4.695 1.926 1.322 3.797
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diabetic complication
ICD Disease Classification 5A2Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glucagon receptor messenger RNA (GCGR mRNA) DTT GCGR 7.24E-02 -0.52 -0.92
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01885260) Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).